Compare iShares MSCI South Korea ETF (EWY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs GeneDx Holdings Corp — how do they compare? iShares MSCI South Korea ETF trades at $177.02 (market cap $26.25B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: iShares MSCI South Korea ETF is far larger — about 13× GeneDx Holdings Corp's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| EWY | WGS | |
|---|---|---|
Market Cap | $26.25B | $2.02B |
Volume | 19,056,075 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $167.51 |
52-Week Low | $80.72 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
